Recent Updates
Recently added Catalysts
Trending News :
The freshest biotech headlines moving stocks right now, newest first.
CapsoVision® Announces International Launch of AI Highlights
CV ▲ 8.97%
SI-BONE, Inc. Reports Financial Results for the Second Quarter 2026 and Raises 2026 Guidance
SIBN ▼ 5.07%
GeneDx Reports Second Quarter 2026 Financial Results
WGS ▼ 7.82%ORIC® Pharmaceuticals Reports Second Quarter 2026 Financial Results and Operational Updates
ORIC ▼ 4.25%
Inspire Medical Systems, Inc. Announces Second Quarter 2026 Financial Results, Raised 2026 Guidance, and Strategic Growth Plan
INSP ▲ 17.55%
Independent Market Assessment Results Show $94 Billion Total Addressable Market for Gemini in Stage 2 and Stage 3 Acute Kidney Injury
REVB ▲ 8.42%
Upcoming Catalysts That Could Move the Market
mRNA-1010, developed by Moderna (MRNA), is current (Read More)
MK-6240, developed by Lantheus Holdings (LNTH), is (Read More)
KEYTRUDA QLEX (pembrolizumab and berahyaluronidase (Read More)
Iberdomide (BMS-986382), developed by Bristol Myer (Read More)
MOLBREEVI (molgramostim) is an inhaled recombinant (Read More)
Deramiocel (CAP-1002), developed by Capricor Thera (Read More)
DTX401 (pariglasgene brecaparvovec), developed by (Read More)
LEQEMBI® IQLIK™ (lecanemab-irmb), developed by Eis (Read More)
Ziihera (zanidatamab-hrii), developed by Jazz Phar (Read More)
Ziihera (zanidatamab-hrii), developed by Zymeworks (Read More)
Gilead Sciences (GILD) is advancing bictegravir 75 (Read More)
Aficamten (MYQORZO) is a small-molecule cardiac my (Read More)
Latest Stocks News :
Apnimed Announces Closing of Upsized Initial Public Offering, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
Apnimed, Inc. has successfully closed its upsized initial public offering, raising $220.8 million through the sale of 13.8 million shares. The offering included the full exercise of underwriters' option to purchase additional shares. Apnimed's common stock began trading on the Nasdaq Global Select Market on July 31, 2026. The company is focused on developing novel therapies for sleep-related breathing diseases, particularly obstructive sleep apnea.
Read more →
ARWRArrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
Arrowhead Pharmaceuticals announced inducement grants for 95 new employees, approved by the Board of Directors under NASDAQ Rule 5635(c)(4). The grants, totaling up to 112,794 restricted stock units, are designed to incentivize new hires and are outside the company's existing equity incentive plans. This move highlights the company's commitment to expanding its workforce.
Read more →HealthStream Announces Second Quarter 2026 Results
HealthStream, Inc. reported strong financial results for the second quarter of 2026, achieving record revenues of $83.7 million, which is a 12.5% increase from the same period in 2025. The operating income also saw a substantial rise of 41.4%, reflecting the company's robust growth in the healthcare technology sector.
Read more →Teladoc Health Appoints Financial Executive Mark Anquillare to Its Board of Directors
Teladoc Health has appointed Mark V. Anquillare to its board of directors. Anquillare, who has over 30 years of financial leadership experience, previously served as president and COO of Verisk Analytics. His background in data and technology is expected to support Teladoc's growth and innovation in virtual care.
Read more →CVCapsoVision® Announces International Launch of AI Highlights
CapsoVision, Inc. has announced the international launch of AI Highlights, a feature for its CapsoCam Plus system designed to enhance the review process of small bowel capsule endoscopy studies. This AI-enabled tool identifies frames with clinically relevant findings, supporting physicians in their assessments. While the product is available in markets like the EU, it has not yet received FDA clearance for use in the U.S.
Read more →UFP Technologies Announces Record Q2 Results
UFP Technologies, Inc. reported impressive financial results for Q2 2026, achieving a net income of $20.9 million, which represents a 21.4% increase from the previous year. The company's net sales also rose by 15.1%, reaching $174.0 million. These results highlight the company's strong performance in the medical device and packaging sectors.
Read more →
TFXTeleflex Completes Strategic Divestiture of OEM Business for $1.5 Billion
Teleflex Incorporated has successfully completed the divestiture of its OEM business to Montagu and Kohlberg for $1.5 billion in cash. This strategic move is part of Teleflex's transformation strategy, allowing the company to concentrate on its core operations and enhance its financial flexibility. The transaction is seen as a significant milestone for the company.
Read more →
HAENew Study Offers Additional Evidence for the VASCADE MVP® XL System's Effectiveness in Electrophysiology Procedures with Large Bore Sheaths
Haemonetics Corporation announced a new study validating the effectiveness of its VASCADE MVP XL system in large-bore sheath procedures. The retrospective study, involving 1,623 patients, showed rapid hemostasis and a high same-day discharge rate. The FDA recently expanded the system's labeling to include larger sheaths, enhancing its applicability in electrophysiology procedures.
Read more →
AEONAEON Biopharma Regains Compliance with NYSE American Continued Listing Standards
AEON Biopharma has announced that it has regained compliance with NYSE American's continued listing standards after addressing previously identified deficiencies. This follows a successful public offering that raised approximately $13.6 million. The company is now positioned to pursue full-label market entry for its biosimilar product ABP-450, which targets the therapeutic neurotoxin market.
Read more →
CRSPCRISPR Therapeutics Provides Business Update and Reports Second Quarter 2026 Financial Results
CRISPR Therapeutics reported strong financial results for Q2 2026, highlighting significant growth in revenue driven by CASGEVY, which is now approved for children aged 2 and older. The company initiated several Phase 1 clinical trials for new therapies, including CTX340 and CTX460. Despite a net loss of $91.2 million, CRISPR maintains a robust cash position of over $2.36 billion, positioning it well for future milestones.
Read more →